Published on 1 Mar 2023 on Zacks via Yahoo Finance
Hologic, Inc. HOLX is gaining from the continued strength of the GYN Surgical and Breast Health businesses. The company’s earnings and revenues in the first quarter of fiscal 2023 beat the Zacks Consensus Estimate. However, stiff competition and currency headwinds do not bode well.
In the past year, this Zacks Rank #2 (Buy) stock has increased 12.4% compared with the 14.8% fall of the industry and the 9.5% fall of the S&P 500.